StreetInsider.com News Articles

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:30:00 -0400

BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that Matt Angel, Ph.D., Tempest’s President and Chief Executive Officer, will present at the H.C. Wainwright 28^th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. ET.

The webcast will be posted to Tempest’s website at https://ir.tempesttx.com and will be archived for two weeks following the presentation.

About Tempest Therapeutics

Tempest

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:30:00 -0400

The webcast will be posted to Tempest’s website at https://ir.tempesttx.com and will be archived for two weeks following the presentation.

About Tempest Therapeutics

Tempest

Form 8-K Tempest Therapeutics, For: Aug 18

Mon, 24 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260824/26968715.html

Form 8-K Tempest Therapeutics, For: Aug 18

Mon, 24 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260824/26968715.html

Form S-1 Tempest Therapeutics,

Fri, 21 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260821/26962001.html

Form S-1 Tempest Therapeutics,

Fri, 21 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260821/26962001.html

Form DEFA14A Tempest Therapeutics,

Tue, 18 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260818/26944778.html

Form DEFA14A Tempest Therapeutics,

Tue, 18 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260818/26944778.html

Form 8-K Tempest Therapeutics, For: Aug 17

Tue, 18 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260818/26944713.html

Form 8-K Tempest Therapeutics, For: Aug 17

Tue, 18 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260818/26944713.html

Form 10-Q Tempest Therapeutics, For: Jun 30

Thu, 13 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260813/26922070.html

Form 10-Q Tempest Therapeutics, For: Jun 30

Thu, 13 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260813/26922070.html

Form 8-K Tempest Therapeutics, For: Aug 13

Thu, 13 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260813/26922028.html

Form 8-K Tempest Therapeutics, For: Aug 13

Thu, 13 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260813/26922028.html

Form 8-K Tempest Therapeutics, For: Aug 13

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921900.html

Form 8-K Tempest Therapeutics, For: Aug 13

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921900.html

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:25:00 -0400

Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027

Unveiled pipeline of next-generation in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD-7 targeted mRNA/LNP delivery approach

Appointed Drake Richey and John Yee, MD, MPH, to Board of Directors

BRISBANE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:25:00 -0400

Unveiled pipeline of next-generation in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD-7 targeted mRNA/LNP delivery approach

Appointed Drake Richey and John Yee, MD, MPH, to Board of Directors

BRISBANE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:25:00 -0400

Unveiled pipeline of next-generation in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD-7 targeted mRNA/LNP delivery approach

Appointed Drake Richey and John Yee, MD, MPH, to Board of Directors

BRISBANE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:25:00 -0400

Unveiled pipeline of next-generation in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD-7 targeted mRNA/LNP delivery approach

Appointed Drake Richey and John Yee, MD, MPH, to Board of Directors

BRISBANE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:

Form DEFA14A Tempest Therapeutics,

Tue, 28 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260728/26828135.html

Form DEFA14A Tempest Therapeutics,

Tue, 28 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260728/26828135.html

Form 8-K Tempest Therapeutics, For: Jul 27

Tue, 28 Jul 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260728/26828092.html

Form 8-K Tempest Therapeutics, For: Jul 27

Tue, 28 Jul 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260728/26828092.html

Form 8-K Tempest Therapeutics, For: Jul 17

Wed, 22 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260722/26801646.html